- Category
- Micro (2021-22)
- Udyam number
- UDYAM-TS-20-0014729

Ditas Labs Private Limited
About Ditas Labs Private Limited
Data last updated:
Ditas Labs Private Limited is a private limited company based in Nizampet, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 April 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24230TG2021PTC150900. Its GSTIN is 36AAICD4637P1Z2 (Telangana).
The company has an authorised share capital of ₹7 Cr and a paid-up capital of ₹6.87 Cr. It is led by directors including Venkata Kishan Suvarna and Nitika Duddilla.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No. 4 & 5 Sy No. 26, Nizampet, Telangana, India – 500090.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.23 Cr. For the same year it recorded a net loss of ₹59.07 Lakh (net margin -48%) and EBITDA of -₹58.89 Lakh (EBITDA margin -47.9%).
Ditas Labs Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-20-0014729).
Company details
Recognitions & Rankings of Ditas Labs
Contact details
Ditas Labs Private Limited's registered office is in Nizampet, Telangana. Its e-mail address is in the company report.
- Email
- Registered AddressPlot No. 4 & 5 Sy No. 26, Nizampet, Telangana, India – 500090
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Ditas Labs Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Ditas Labs is manufacturing. In detail, this covers manufacture of chemicals and chemical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 20 | Manufacture of chemicals and chemical products |
To see the full business activity and turnover split of Ditas Labs Private Limited, buy the company report.
Financials of Ditas Labs Private Limited
FY 2025 filings availableDitas Labs Private Limited reported revenue of ₹1.23 Cr for FY 2025.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | -₹58.89 Lakh | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | -₹59.07 Lakh | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | -47.9% | |||
| Net Profit Margin | -48% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Ditas Labs Private Limited, buy the company report.
Board of directors of Ditas Labs Private Limited
Ditas Labs has 5 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Venkata Kishan Suvarna | Director | 03 Jun 2021 | 5 Years 4 Months | Current |
| Nitika Duddilla Also directs: Divinitus LLP, Ditas Infra Private Limited, Divinitus Infrasturcture Private Limited and 4 more | Director | 03 Jun 2021 | 5 Years 4 Months | Current |
| Chaturya Yarlagadda Also directs: Polar Cubs Academy LLP | Director | 23 Apr 2021 | 5 Years 6 Months | Current |
| Yarlagadda Vinoothna Chowdhary Also directs: Sri Phoenixe Drugs & Chemicals Private Limited | Director | 23 Apr 2021 | 5 Years 6 Months | Current |
| Srinivas Duddilla Also directs: Divinitus LLP, Ditas Infra Private Limited, Divinitus Infrasturcture Private Limited and 2 more | Director | 23 Apr 2021 | 5 Years 6 Months | Current |
Peer comparison
Ditas Labs Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (manufacture of chemicals and chemical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Meghdoot Chemicals Limited | ₹1.26 Cr (FY 2025) | 25.0% | Bhiwandi, Maharashtra, India | |||
| Maxolay Coatings Private Limited | ₹1.26 Cr (FY 2024) | 3682.0% | Ahmedabad, Gujarat, India | |||
| Velour Touch Private Limited | ₹1.25 Cr (FY 2025) | 19.0% | Jagadhri, Haryana, India | |||
| Tanya Petrochemicals Private Limited | ₹1.23 Cr (FY 2025) | -63.0% | Bhopal, Madhya Pradesh, India | |||
| Nasg Polycompounds Private Limited | ₹1.23 Cr (FY 2025) | -26.0% | Chennai, Tamil Nadu, India | |||
| Ditas Labs Private Limitedthis company | ₹1.23 Cr (FY 2025) | -₹59.07 Lakh | -48% | Nizampet, Telangana, India | ||
| Golden Pigments Pvt.Ltd. | ₹1.22 Cr (FY 2025) | -7.0% | New Delhi, Delhi, India | |||
| Ampaliya Chemicals Private Limited | ₹1.22 Cr (FY 2024) | Sanand, Gujarat, India | ||||
| Sanvincare India Private Limited | ₹1.22 Cr (FY 2025) | 7.0% | Bhopal, Madhya Pradesh, India | |||
| Nature Crete Building Adhesives Private Limited | ₹1.21 Cr (FY 2024) | 108.0% | Bangalore, Karnataka, India | |||
| Hikqs Enterprises Private Limited | ₹1.21 Cr (FY 2025) | 259.0% | Haldwani, Uttarakhand, India |
To see the full peer comparison of Ditas Labs Private Limited, buy the company report.
Auditor
Ditas Labs Private Limited is audited by PPKG & CO for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PPKG & CO | FY 2023 | 009655S |
Shareholding
The shareholding of Ditas Labs Private Limited is on record for FY 2022, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2022 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Ditas Labs Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Ditas Labs Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ditas Labs Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Ditas Labs Private Limited has 1 active EPFO establishment as of Apr 09, 2024.
GST
Ditas Labs has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAICD4637P1Z2 | Telangana | Active | 27 May 2021 |
To see the full GST registrations and return filing status of Ditas Labs Private Limited, buy the company report.
Recent activity
Ditas Labs Private Limited has 7 board changes on record since 2021: 6 appointments and 1 cessation. The latest: Chaturya Yarlagadda ceased to be Individual Promoter on 06 Feb 2026.
Frequently asked questions
Ditas Labs is an active private limited company based in Nizampet, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 April 2021 (5+ years old) and is registered under CIN U24230TG2021PTC150900.
Ditas Labs has 5 current directors:
- Venkata Kishan Suvarna - Director
- Nitika Duddilla - Director
- Chaturya Yarlagadda - Director
- Yarlagadda Vinoothna Chowdhary - Director
- Srinivas Duddilla - Director
The latest financial statements of Ditas Labs on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2022 are in the company report.
The GSTIN of Ditas Labs is 36AAICD4637P1Z2, registered in Telangana.
The CIN (Corporate Identification Number) of Ditas Labs is U24230TG2021PTC150900. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ditas Labs was incorporated on 23 April 2021, making it 5+ years old. It is registered with the Registrar of Companies, Hyderabad.
The peers of Ditas Labs by revenue are Meghdoot Chemicals Limited, Maxolay Coatings Private Limited, Velour Touch Private Limited, Tanya Petrochemicals Private Limited, Nasg Polycompounds Private Limited and 5 more, all in the same principal business activity (manufacture of chemicals and chemical products).
Chaturya Yarlagadda ceased to be Individual Promoter on 06 Feb 2026. Nitika Duddilla was appointed as Director on 03 Jun 2021. Venkata Kishan Suvarna was appointed as Director on 03 Jun 2021. Ditas Labs has 7 board changes on record in total.
Yes, Ditas Labs is registered as a micro enterprise under Udyam registration (number: UDYAM-TS-20-0014729).
The registered office of Ditas Labs is at Plot No. 4 & 5 Sy No. 26, Nizampet, Telangana, India – 500090.
Ditas Labs operates in the pharma industry, in the drug formulation and development segment.

